Role of natriuretic peptides in cardiovascular surgery

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 5, 2009, Pages 515-519

  Shimada, Michiko ^a,b   Ejaz, A Ahsan ^b   Beaver, Thomas M ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acute kidney injury; Cardiovascular surgery; Natriuretic peptide

Indexed keywords

NATRIURETIC FACTOR;

ACUTE KIDNEY TUBULE NECROSIS; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIURESIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; KIDNEY INJURY; MITRAL VALVE REPAIR; POSTOPERATIVE COMPLICATION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; SURGICAL RISK; SURVIVAL RATE; VASODILATATION; ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; PHYSIOLOGY; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY FAILURE, ACUTE; NATRIURETIC PEPTIDES; RISK ASSESSMENT;

EID: 68949205609     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.20     Document Type: Review

References (42)

1. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam. Clin. Pharmacol. 19, 411-419 (2005).
2. + current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. Am. J. Physiol. Heart Circ. Physiol. 285(6), H2454-H2462 (2003).
3. Huxley VH, Tucker VL, Verburg KM, Freeman RK. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ. Res. 60, 304-307 (1987).
4. McKay MK, Huxley VH. ANP increases capillary permeability to protein independent of perfusate protein composition. Am. J. Physiol. 268, H1139-H1148 (1995).
5. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human natriuretic peptide on human artery and vein tissue. Am. J. Hypertens. 9, 432-436 (1996).
6. Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am. J. Physiol. 261, F1102-F1109 (1991).
7. Huang CL, Lewicki J, Johnson LK, Cogan MG. Renal mechanism of action ef rat atrial natriuretic factor. J. Clin. Invest. 75, 769-773 (1985).
8. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111, 1487-1491 (2005).
9. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900-1905 (2005).
10. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 296, 1465-1466 (2006).
11. Colucci WS, Elkayam U, Horton DP et al.; Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med. 343, 246-253 (2000).
12. Burger AJ, Horton DP, LeJemtel T et al. Prospective randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. 144, 1102-1108 (2002).
13. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am. J. Emerg. Med. 23, 327-331 (2005).
14. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531-1540 (2002).
15. Yancy CW, Saltzberg MT, Berkowitz RL et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am. J. Cardiol. 94, 595-601 (2004).
16. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84, 1581-1588 (1991).
17. Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J. Card. Fail. 2, S277-S285 (1996).
18. Lainchbury JG, Richards AM, Nicholls MG et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension 30, 398-404 (1997).
19. Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94, 3184-3189 (1996).
20. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest. Heart Fail. 11, 30-38 (2005).
21. Hayashi Y, Ohtani M, Hiraishi T, Kobayashi Y. Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide. J. Thorac. Cardiovasc. Surg. 124, 206-209 (2002).
22. Beaver TM, Winterstein A, Hess PJ Jr et al. Nesiritide following maze and mitral valve surgery. J. Card. Surg. 23, 431-436 (2008).
23. Rahman SN, Kim GE, Mathew AS et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 45, 1731-1738 (1994).
24. Allgren RL, Marbury TC, Rahman SN et al.; Auriculin Anaritide Acute Renal Failure Study Group. Anaritide in acute tubular necrosis. N. Engl. J. Med. 336, 828-834 (1997).
25. Lewis J, Salem MM, Chertow GM et al.; Anaritide Acute Renal Failure Study Group. Atrial natriuretic factor in oliguric acute renal failure. Am. J. Kidney-Dis. 36, 767-774 (2000).
26. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4(2), 261-272 (2009).
27. Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Int. Care Med. 22, 230-236 (1996).
28. Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit. Care Med. 32(6), 1310-1315 (2004).
29. Beaver TM, Winterstein AG, Shuster JJ et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin. Cardiol. 29, 18-24 (2006).
30. Mentzer RM Jr, Oz MC, Sladen RN et al.; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J. Am. Coll. Cardiol. 49, 716-726 (2007).
31. Ejaz AA, Martin TD, Johnson RJ et al. Prophylactic nesiritide does not prevent dialysis or all cause mortality in high-risk cardiac surgery patients. J. Vasc. Cardiothorac. Surg. (2009) (In Press).
32. Ejaz AA, Heinig ME, Kazory A, Bihorac A, Hobson CE, Beaver TM. The rise and fall of natriuretic peptides in acute kidney injury: a misunderstood relationship? Rev. Cardiovasc. Med. 8(Suppl. 5), S32-S37 (2007).
33. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 17, 1503-1520 (2006).
34. Mehta RL, Kellum JA, Shah SV et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11(2), R31 (2007).
35. Ponte B, Felipe C, Muriel A, Tenorio MT, Liaño F. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol. Dial. Transplant. 23, 3859-3866 (2008).
36. Chen HH, Sundt TM, Cook DJ. Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 116, I134-138 (2007).
37. Dyke CM, Bhatia D, Aronson S, Moazami N, Mentzer RM Jr. Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction. J. Thorac. Cardiovasc. Surg. 136, 1369-1370 (2008).
38. Yavas S, Segal MS, Sungur M, Gabrielli A, Layon AJ, Bihorac A. Postoperative Acute kidney injury is an important determinant of long term survival of surgical patients. Blood Purif. 25, 183-208 (2007).
39. Leacche M, Rawn JD, Mihaljevic T et al. Outcomes in patients with normal serum creatinine and with artificial renal support for acute renal failure developing after coronary artery bypass grafting. Am. J. Cardiol. 93, 353-356 (2004).
40. Loef BG, Epema AH, Smilde TD et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J. Am. Soc. Nephrol. 16, 195-200 (2005).
41. Oeyen S, Vandijck D, Benoit D, Decruyenaere J, Annemans L, Hoste E. Long-term outcome after acute kidney injury in critically-ill patients. Acta Clin. Belg. 2, 337-340 (2007).
42. Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int. 67, 1112-1119 (2005).